A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer

Axel Grothey

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Oral capecitabine has been shown to be a convenient and well tolerated alternative to intravenous 5-fluorouracil (5-FU) in the treatment of colorectal cancer. The question of whether capecitabine is an adequate and equally effective substitute for infusional 5-FU in combination with oxaliplatin for the treatment of advanced colorectal cancer has long been unanswered. On the basis of results from the randomized, phase III trial by Cassidy et al., capecitabine in combination with oxaliplatin has emerged as a valid treatment alternative to infusional 5-FU in combination with oxaliplatin in patients with advanced colorectal cancer. For patients treated in the US, however, questions about the most appropriate dosage and schedule of capecitabine have not yet been completely resolved. Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study.

Original languageEnglish (US)
Pages (from-to)10-11
Number of pages2
JournalNature Clinical Practice Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2009

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this